Galmed Pharmaceuticals (GLMD) EBITDA (2012 - 2025)
Galmed Pharmaceuticals (GLMD) EBITDA from Dec 31, 2012 to Dec 31, 2025. The TTM Galmed Pharmaceuticals (GLMD) EBITDA is -$10M. You can adjust inflation or export chart.
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Annual EBITDA
Galmed Pharmaceuticals (GLMD) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year | +38.76% |
| 3 Years | -16.69% |
| 5 Years | -19.33% |
| 10 Years | -0.25% |
| All Time | +9.58% |
Annual EBITDA change of Galmed Pharmaceuticals (GLMD)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$10M | +38.76% |
| 2024 | -$7.43M | +7.99% |
| 2023 | -$6.88M | -61.41% |
| 2022 | -$18M | -45.00% |
| 2021 | -$32M | +7.46% |
| 2020 | -$30M | +35.05% |
| 2019 | -$22M | +116.26% |
| 2018 | -$10M | -14.77% |
| 2017 | -$12M | -27.34% |
| 2016 | -$17M | +57.81% |
| 2015 | -$11M | +16.28% |
| 2014 | -$9.09M | -48.00% |
| 2013 | -$17M | +456.69% |
| 2012 | -$3.14M | N/A |
Comparison Galmed Pharmaceuticals (GLMD) five years EBITDA CAGR with competitors
Galmed Pharmaceuticals (GLMD) five years EBITDA CAGR is -19.33%.